Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Erythropoietin (EPO) in Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hohen and Yahr´s Scale between I and III~* One or more years of evolution of PD,~* Good response to levodopa (more that 30 % of change)valued in motor UPDRS~* An acceptable general health status,~Exclusion Criteria:~* Chronic psychiatric or other neurological diseases.~* Previous polyglobulin~* Hematocryte, same or inferior to 50

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Erythropoietin (Type: EXPERIMENTAL): There are evidences of neuroprotecting therapeutic alternatives in such substances as erythropoietin (EPO) which is a well-known cytokine as a hematopoietic growth factor, so, it is therefore important to control tissular oxygenation. It is considered that EPO protects the neurons by a combination of several mechanisms.~EPOrh is used with high effectiveness in the treatment of anemias with deficiency of erythropoietin.

Based on this trial design, predict the completion outcome and termination type (if applicable).